Wildon Farwell Selected Research

nusinersen

1/2022	Nusinersen by subcutaneous intrathecal catheter for symptomatic spinal muscular atrophy patients with complex spine anatomy.
1/2021	Treatment of infantile-onset spinal muscular atrophy with nusinersen: final report of a phase 2, open-label, multicentre, dose-escalation study.
1/2021	Population pharmacokinetics-based recommendations for a single delayed or missed dose of nusinersen.
1/2021	Safety and efficacy of nusinersen in spinal muscular atrophy: The EMBRACE study.
11/2019	Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: Interim efficacy and safety results from the Phase 2 NURTURE study.
10/2019	Nusinersen improves walking distance and reduces fatigue in later-onset spinal muscular atrophy.
1/2019	Nusinersen in later-onset spinal muscular atrophy: Long-term results from the phase 1/2 studies.
1/2019	An Integrated Safety Analysis of Infants and Children with Symptomatic Spinal Muscular Atrophy (SMA) Treated with Nusinersen in Seven Clinical Trials.
1/2018	Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy.
11/2017	Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Wildon Farwell Research Topics

Disease

14	Spinal Muscular Atrophy (Progressive Muscular Atrophy) 01/2022 - 11/2017
2	Infections 01/2022 - 01/2017
1	Congenital Abnormalities (Deformity) 01/2022
1	Fatigue 10/2019
1	Headache (Headaches) 01/2019
1	Constipation 01/2019
1	Fever (Fevers) 01/2019
1	Nasopharyngitis 01/2019
1	Respiratory Tract Infections (Respiratory Tract Infection) 01/2019
1	Vomiting 01/2019
1	Hypereosinophilic Syndrome (Loeffler Endocarditis) 01/2017
1	Amyotrophic Lateral Sclerosis (Lou Gehrig's Disease) 01/2017
1	Chronic Kidney Failure (Chronic Renal Failure) 12/2014
1	Dementia (Dementias) 11/2009
1	Bradycardia 11/2009

Drug/Important Bio-Agent (IBA)

10	nusinersenIBA 01/2022 - 11/2017
2	Biomarkers (Surrogate Marker)IBA 01/2021 - 05/2019
2	salicylhydroxamic acid (SHAM)IBA 01/2018 - 11/2017
2	DexpramipexoleIBA 01/2017 - 12/2014
1	Antisense OligonucleotidesIBA 01/2021
1	Proteins (Proteins, Gene)FDA Link 11/2017
1	Adrenal Cortex Hormones (Corticosteroids)IBA 01/2017
1	Donepezil (Aricept)FDA LinkGeneric 11/2009
1	Cholinesterase Inhibitors (Anticholinesterases)IBA 11/2009

Therapy/Procedure

3	Therapeutics 12/2021 - 01/2017
1	Catheters 01/2022
1	Renal Dialysis (Hemodialysis) 12/2014